Trial · NCT04856930
Participant flow27
How many started, completed or left each group, period by period.
1 to 20 of 27
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Placebo-controlled Period (16 Weeks) | STARTED | Imsidolimab 400/200 mg | 50 | |
| Placebo-controlled Period (16 Weeks) | STARTED | Imsidolimab 200/100 mg | 50 | |
| Placebo-controlled Period (16 Weeks) | STARTED | Placebo | 49 | |
| Placebo-controlled Period (16 Weeks) | COMPLETED | Imsidolimab 400/200 mg | 41 | |
| Placebo-controlled Period (16 Weeks) | COMPLETED | Imsidolimab 200/100 mg | 42 | |
| Placebo-controlled Period (16 Weeks) | COMPLETED | Placebo | 43 | |
| Placebo-controlled Period (16 Weeks) | NOT COMPLETED | Imsidolimab 400/200 mg | 9 | |
| Placebo-controlled Period (16 Weeks) | NOT COMPLETED | Imsidolimab 200/100 mg | 8 | |
| Placebo-controlled Period (16 Weeks) | NOT COMPLETED | Placebo | 6 | |
| Extension Period (16 Weeks) | STARTED | Imsidolimab 400/200 mg | 41 | |
| Extension Period (16 Weeks) | STARTED | Imsidolimab 200/100 mg | 42 | |
| Extension Period (16 Weeks) | STARTED | Placebo | 43 | |
| Extension Period (16 Weeks) | COMPLETED | Imsidolimab 400/200 mg | 28 | |
| Extension Period (16 Weeks) | COMPLETED | Imsidolimab 200/100 mg | 32 | |
| Extension Period (16 Weeks) | COMPLETED | Placebo | 35 | |
| Extension Period (16 Weeks) | NOT COMPLETED | Imsidolimab 400/200 mg | 13 | |
| Extension Period (16 Weeks) | NOT COMPLETED | Imsidolimab 200/100 mg | 10 | |
| Extension Period (16 Weeks) | NOT COMPLETED | Placebo | 8 | |
| Follow-up Period (8 Weeks) | STARTED | Imsidolimab 400/200 mg | 28 | |
| Follow-up Period (8 Weeks) | STARTED | Imsidolimab 200/100 mg | 32 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04856930/flow